Lenalidomide induces degradation of IKZF1 and IKZF3 #MMPMID25610725
Krönke J; Hurst SN; Ebert BL
Oncoimmunology 2014[]; 3 (7): ä PMID25610725show ga
Lenalidomide and its analogs, thalidomide and pomalidomide, specifically inhibit growth of mature B-cell lymphomas, including multiple myeloma, and induce interleukin-2 (IL-2) release from T cells. We recently found that this results from activation of the CRBN-CRL4 E3 ubiquitin ligase to degrade the lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos).